Development of ipilimumab: a novel immunotherapeutic approach for the treatment of advanced melanoma.
about
Myeloid Cells as Targets for Therapy in Solid TumorsWhich Metrics Are Appropriate to Describe the Value of New Cancer Therapies?Review of immune-related adverse events in prostate cancer patients treated with ipilimumab: MD Anderson experienceNovel immunotherapies for hematologic malignanciesCD28 co-stimulation in T-cell homeostasis: a recent perspectiveThe Evolving Role of Immune Checkpoint Inhibitors in Cancer TreatmentOncolytic viruses as anticancer vaccinesPD-1 and PD-L1 antibodies for melanomaPharmacologic management of advanced cervical cancer: antiangiogenesis therapy and immunotherapeutic considerationsClinical experience with ipilimumab 3 mg/kg: real-world efficacy and safety data from an expanded access programme cohort.Pooled Analysis of Long-Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic MelanomaMechanism of tumor rejection with doublets of CTLA-4, PD-1/PD-L1, or IDO blockade involves restored IL-2 production and proliferation of CD8(+) T cells directly within the tumor microenvironment.Opportunistic Autoimmune Disorders Potentiated by Immune-Checkpoint Inhibitors Anti-CTLA-4 and Anti-PD-1Antibody-mediated neutralization of soluble MIC significantly enhances CTLA4 blockade therapy.Dextran as a generally applicable multivalent scaffold for improving immunoglobulin-binding affinities of peptide and peptidomimetic ligands.A phase I study of the investigational NEDD8-activating enzyme inhibitor pevonedistat (TAK-924/MLN4924) in patients with metastatic melanoma.Prolonged repeated vaccine immuno-chemotherapy induces long-term clinical responses and survival for advanced metastatic melanoma.Immune therapy for human papillomaviruses-related cancers.Intratumoral injection of IFN-alpha dendritic cells after dacarbazine activates anti-tumor immunity: results from a phase I trial in advanced melanoma.Beyond adjuvants: immunomodulation strategies to enhance T cell immunityCancer immunotherapy and immune-related response assessment: The role of radiologists in the new arena of cancer treatment.Gene therapy for cancer: present status and future perspectivePhase I study of ipilimumab in phased combination with paclitaxel and carboplatin in Japanese patients with non-small-cell lung cancer.Impact of Diverse Immune Evasion Mechanisms of Cancer Cells on T Cells Engaged by EpCAM/CD3-Bispecific Antibody Construct AMG 110Randomized phase II/III clinical trial of elpamotide for patients with advanced pancreatic cancer: PEGASUS-PC Study.Improved survival with T cell clonotype stability after anti-CTLA-4 treatment in cancer patients.Vogt-Koyanagi-Harada-like syndrome after CTLA-4 inhibition with ipilimumab for metastatic melanomaTwo heads better than one? Ipilimumab immunotherapy and radiation therapy for melanoma brain metastases.Preclinical Development of Ipilimumab and Nivolumab Combination Immunotherapy: Mouse Tumor Models, In Vitro Functional Studies, and Cynomolgus Macaque ToxicologyPhase II study of ipilimumab monotherapy in Japanese patients with advanced melanoma.Circulating Tumor Cells, DNA, and mRNA: Potential for Clinical Utility in Patients With Melanoma.Targeted therapies in gastric cancer and future perspectives.Melanoma growth effects on molecular clearance from tumors and biodistribution into systemic tissues versus draining lymph nodes.Vaccines Combined with Immune Checkpoint Antibodies Promote Cytotoxic T-cell Activity and Tumor Eradication.Survival follow-up and ipilimumab retreatment of patients with advanced melanoma who received ipilimumab in prior phase II studies.Immune response and the tumor microenvironment: how they communicate to regulate gastric cancer.Neuroinflammatory and cognitive consequences of combined radiation and immunotherapy in a novel preclinical model.Efficacy and safety of ipilimumab in elderly patients with pretreated advanced melanoma treated at Italian centres through the expanded access programmeEomesodermin is required for antitumor immunity mediated by 4-1BB-agonist immunotherapy.Immunotherapy for malignant pleural mesothelioma. Current status and future prospects.
P2860
Q26801832-52981181-7484-4A7E-9741-D0F6AB939BABQ26858853-9A5F0AFA-23E7-4B56-BCD9-59173F9CAAA5Q26995499-11B3CC23-BBE7-48C1-BAC4-22F3C709307CQ27004436-0C4B0009-1DC1-43EA-8B71-4209D89E621FQ27007031-BE7A548F-426A-4D42-925B-7DED5F7C90CEQ27022789-D9BEAE7E-75B9-4BA7-B413-A4CB6B0A873CQ27025600-1A0988D0-D5A9-4AC7-BC0B-AB4EB73175FFQ28081882-006B0BDC-D48E-406C-AD42-C93399953C6EQ28086919-A5322E67-7E4D-4CBD-8817-53A8A0A6B07FQ30828178-D7BEF1DA-04A4-4BF9-9191-DF1AC8724494Q30890582-45055E22-F1C2-4322-9AFF-ABD0A2B1503DQ33606150-AF8A5591-D65D-4596-AB32-FA773A946984Q33658400-FE56E12B-6D1C-48E0-BE67-B66C7BB86271Q33699687-6E4E68CB-E593-4409-8C89-0FC86A85CC00Q34431415-EC56E8E5-21A2-407A-B770-E915B8BCF507Q34521260-C113807C-870C-4DA4-9F35-B6A668136DFCQ34534663-4B978E7E-4C01-4FB1-B803-B85926529BEEQ34657561-2A1CD4C5-BFB2-4717-B90B-026DA64A6A69Q35627237-E4202887-0860-402A-87B6-3161F776C443Q35666506-1E8B26E9-E131-41DD-BA9C-478261DEF512Q35668604-F69C9ADF-C925-4459-AA9D-1A6B0DAB85F3Q35673900-603C7D11-500D-4BD3-9D17-BB09C04B6B0DQ35817265-C051FFDD-4678-49A2-B488-D18AA01FE86BQ35824663-E4E2207B-46AB-468E-9B10-9BE6E3ADDCFAQ35904219-2F21E422-94D6-4EA8-8E1C-15076274747AQ36020800-8DFF8D3D-F8A5-4259-8808-979401FE657CQ36041848-04AD5150-8123-4590-A459-678629B05FCAQ36082506-D116822A-0C54-4ADC-910F-8A0909FCDBBAQ36127709-C56309F8-C264-467C-A05D-27EC75B7E8C8Q36181274-0F338E8C-9C1B-462C-900A-549250115A8BQ36452245-01D06A90-DE1E-4447-B06E-F0E459E46367Q36471685-5B77F8FA-F6CB-4630-85B5-01BBD554E9DBQ36494851-325A09AA-D1A2-451E-845F-6AF2C4A9F5ADQ36540614-706BCB43-3F02-4090-AD6B-528D843ED3CCQ37188758-B4F14F6C-4D7A-4C9E-B17B-8F2F0391C040Q37660381-FF7038B4-9B36-431A-93B7-A26E44835280Q37705929-C936BE33-BBCD-486E-A2DE-72A3292CE0E6Q37718203-7CD1427A-D44D-4327-8653-64FDDA34442FQ37728543-88B54831-EE20-4276-A243-28FFB22F333FQ38180749-48252974-06B3-4376-891E-02FE4D7E1862
P2860
Development of ipilimumab: a novel immunotherapeutic approach for the treatment of advanced melanoma.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 17 June 2013
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Development of ipilimumab: a n ...... reatment of advanced melanoma.
@en
Development of ipilimumab: a n ...... reatment of advanced melanoma.
@nl
type
label
Development of ipilimumab: a n ...... reatment of advanced melanoma.
@en
Development of ipilimumab: a n ...... reatment of advanced melanoma.
@nl
prefLabel
Development of ipilimumab: a n ...... reatment of advanced melanoma.
@en
Development of ipilimumab: a n ...... reatment of advanced melanoma.
@nl
P2093
P2860
P921
P356
P1476
Development of ipilimumab: a n ...... reatment of advanced melanoma.
@en
P2093
Alan J Korman
David M Berman
F Stephen Hodi
Jedd D Wolchok
Jeffrey S Weber
Nils Lonberg
Rachel Humphrey
Steven J O'Day
Walter J Urba
P2860
P356
10.1111/NYAS.12180
P407
P5008
P577
2013-06-17T00:00:00Z
2013-07-01T00:00:00Z